Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.4 GBX
Market Closed
Updated:
May 14, 2024
Fusion Antibodies PLC
Cash & Cash Equivalents
|
Fusion Antibodies PLC
Cash & Cash Equivalents Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Cash & Cash Equivalents
£487k
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Cash & Cash Equivalents
£220.5m
|
CAGR 3-Years
40%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Cash & Cash Equivalents
£28.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Cash & Cash Equivalents
£19.8m
|
CAGR 3-Years
19%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Cash & Cash Equivalents
£26m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Cash & Cash Equivalents
£37m
|
CAGR 3-Years
24%
|
CAGR 5-Years
106%
|
CAGR 10-Years
71%
|
See Also
What is Fusion Antibodies PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
487k
GBP
487k
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Cash & Cash Equivalents amounts to 487k GBP.
What is Fusion Antibodies PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-30%
-30%
Over the last year, the Cash & Cash Equivalents growth was -59%. The average annual Cash & Cash Equivalents growth rates for Fusion Antibodies PLC have been -47% over the past three years , -30% over the past five years .
You don't have any saved screeners yet
